WO2002061418A1 - Procede de criblage de facteur d'infection de maladie a prion - Google Patents

Procede de criblage de facteur d'infection de maladie a prion Download PDF

Info

Publication number
WO2002061418A1
WO2002061418A1 PCT/JP2002/000803 JP0200803W WO02061418A1 WO 2002061418 A1 WO2002061418 A1 WO 2002061418A1 JP 0200803 W JP0200803 W JP 0200803W WO 02061418 A1 WO02061418 A1 WO 02061418A1
Authority
WO
WIPO (PCT)
Prior art keywords
screening
prion disease
disease infection
prion
nonhuman
Prior art date
Application number
PCT/JP2002/000803
Other languages
English (en)
French (fr)
Inventor
Tetsuyuki Kitamoto
Kazurou Miyoshi
Shirou Mohri
Original Assignee
Japan As Represented By President Of Tohoku University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By President Of Tohoku University filed Critical Japan As Represented By President Of Tohoku University
Priority to NZ527769A priority Critical patent/NZ527769A/en
Priority to EP02710440A priority patent/EP1394542A4/en
Priority to CA002437016A priority patent/CA2437016A1/en
Priority to AU2002228403A priority patent/AU2002228403B9/en
Priority to US10/470,848 priority patent/US7452709B2/en
Priority to KR1020037010113A priority patent/KR100544933B1/ko
Publication of WO2002061418A1 publication Critical patent/WO2002061418A1/ja

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/JP2002/000803 2001-01-31 2002-01-31 Procede de criblage de facteur d'infection de maladie a prion WO2002061418A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
NZ527769A NZ527769A (en) 2001-01-31 2002-01-31 Method of screening prion disease infection factor
EP02710440A EP1394542A4 (en) 2001-01-31 2002-01-31 SCREENING PROCEDURE FOR A PRIONE DISEASE INFECTION FACTOR
CA002437016A CA2437016A1 (en) 2001-01-31 2002-01-31 Screening method for infection agent of prion disease
AU2002228403A AU2002228403B9 (en) 2001-01-31 2002-01-31 Method of screening prion disease infection factor
US10/470,848 US7452709B2 (en) 2001-01-31 2002-01-31 Method of screening prion disease infection factor
KR1020037010113A KR100544933B1 (ko) 2001-01-31 2002-01-31 프리온병 감염인자의 스크리닝 방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001024279A JP3421744B2 (ja) 2001-01-31 2001-01-31 プリオン病感染因子のスクリーニング方法
JP2001-24279 2001-01-31

Publications (1)

Publication Number Publication Date
WO2002061418A1 true WO2002061418A1 (fr) 2002-08-08

Family

ID=18889436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/000803 WO2002061418A1 (fr) 2001-01-31 2002-01-31 Procede de criblage de facteur d'infection de maladie a prion

Country Status (8)

Country Link
US (1) US7452709B2 (ja)
EP (2) EP1972935A1 (ja)
JP (1) JP3421744B2 (ja)
KR (1) KR100544933B1 (ja)
AU (1) AU2002228403B9 (ja)
CA (1) CA2437016A1 (ja)
NZ (1) NZ527769A (ja)
WO (1) WO2002061418A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ569448A (en) * 2005-12-08 2011-12-22 Univ South Dakota Method of in vitro propagation and detection of infectious prion using follicular dendritic cell cultures co-cultured with B cells
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
EP2627357B1 (en) * 2010-10-15 2017-05-03 The Board of Regents of The University of Texas System Antibodies that bind amyloid oligomers
CN102879577B (zh) * 2012-11-01 2014-04-09 山东龙美生物医学科技有限公司 一种检测朊病毒的试剂盒及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908969A (en) * 1994-05-13 1999-06-01 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
AU5287800A (en) * 1999-05-26 2000-12-12 Regents Of The University Of California, The Models of prion disease
JP2001024279A (ja) 1999-07-09 2001-01-26 Matsushita Electric Ind Co Ltd 半導体レーザ素子の製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KENJI NAKAMURA: "No kino to ijo no hatsugen no kaiseki model kei no kaihatsu ni kansuru kenkyu, no kino no gairai inshi ni yoru ijo hatsugen kiko kaimei no tameno gijutsu kaihatsu ni kansuru kenkyu (dai II ki; heisei 7 to 9 nendo (1995 to 1997)", SEIKA HOKUSHO, HEISEI 11 NEN, March 1999 (1999-03-01), pages 221 - 228, XP002955004 *
MOHRI, S. AND KITAMOTO, T.: "Mouse prion no FDC ni okeru shoki chinchaku, koseisho tokutei shikkan chihatsusei virus kansen chosa kenkyuhan heisei 8 nen (1996)", KENKYU HOKOKUSHO HEISEI 9 NEN, March 1997 (1997-03-01), pages 37 - 42, XP002955003 *
NAKAMURA, K. ET AL: "Jikken dobutsu ni okeru hito idenshi hatsugenkei no kaihatsu, koseisho tokutei shikkan chihatsusei virus kansen chosa kenkyuhan heisei 8 nendo (1996)", KENKYU HOKOKUSHO, HEISEI 9 NEN, March 1997 (1997-03-01), pages 25 - 28, XP002955005 *
See also references of EP1394542A4 *

Also Published As

Publication number Publication date
KR100544933B1 (ko) 2006-01-24
JP2002228665A (ja) 2002-08-14
AU2002228403B9 (en) 2005-03-10
EP1972935A1 (en) 2008-09-24
AU2002228403B2 (en) 2005-03-03
JP3421744B2 (ja) 2003-06-30
CA2437016A1 (en) 2002-08-08
US20040137421A1 (en) 2004-07-15
EP1394542A1 (en) 2004-03-03
US7452709B2 (en) 2008-11-18
NZ527769A (en) 2005-05-27
KR20030079974A (ko) 2003-10-10
EP1394542A4 (en) 2004-05-19

Similar Documents

Publication Publication Date Title
Wolff et al. Protein glycation and oxidative stress in diabetes mellitus and ageing
Wilker et al. Chromatographic quantification of argpyrimidine, a methylglyoxal-derived product in tissue proteins: comparison with pentosidine
AU2002952548A0 (en) Diagnostic assay
WO2005012553A3 (en) Optical in vivo probe of analyte concentration within the sterile matrix under the human nail
WO2004063704A3 (en) Vitamin d assay
WO2008028489A3 (en) Ip-i0 based immunological monitoring
Cinq-Mars et al. Optimizing angiotensin I-converting enzyme inhibitory activity of Pacific hake (Merluccius productus) fillet hydrolysate using response surface methodology and ultrafiltration
EP2287618A3 (en) Method for diagnosing neuro-degenerative disease
WO2001082793A3 (en) Method and device for testing a sample of fresh whole blood
WO2002084250A3 (en) Methods for mass spectrometry detection and quantification of specific target proteins in complex biological samples
Kangsanant et al. Purification and characterisation of antioxidant and nitric oxide inhibitory peptides from T ilapia (O reochromis niloticus) protein hydrolysate
WO2001064738A3 (fr) Sequences d"acides amines derivees des proteines humaines reagissant avec l"heparine facilitant le transfert de substances d"interet a l"interieur des cellules et/ou des noyaux cellulaires
WO2002061418A1 (fr) Procede de criblage de facteur d'infection de maladie a prion
AU2003296085A1 (en) Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same
WO2003082335A1 (fr) Nouveau dispositif de controle du sucre dans le sang et procede de criblage associe
WO2004072295A3 (en) Strokes shift emission spectroscopy for detection of disease and physiological state of specimen
CA2406443A1 (en) Method for quantification of akt protein expression
WO2004071273A3 (en) Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus
PL1723172T3 (pl) Ciekły preparat erytropoetyny
RU2007135360A (ru) Способ измерения поглощенной дозы ионизирующего излучения
AU2003302499A1 (en) Methods for antigen masking of red blood cells resulting in reduced hemolysis
ATE433462T1 (de) Me-5, me-2, and epp2: menschliche proteinantigene,die mit autoantikörpern reagieren, die im serum von frauen vorliegen, die an endometriose leiden
WO2004083392A3 (en) Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
WO2004093662A3 (en) Method for detecting prognosis of cancer
EP1315966B1 (en) Method of monitoring the effect of cathepsin s inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA KR NZ US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2437016

Country of ref document: CA

Ref document number: 1020037010113

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10470848

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 527769

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002228403

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002710440

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037010113

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2002710440

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 527769

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002228403

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 527769

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 1020037010113

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2002710440

Country of ref document: EP